Sumitomo Pharma Past Earnings Performance
Past criteria checks 0/6
Sumitomo Pharma's earnings have been declining at an average annual rate of -71.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 5.9% per year.
Key information
-71.7%
Earnings growth rate
-71.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -5.9% |
| Return on equity | -244.6% |
| Net Margin | -81.6% |
| Next Earnings Update | 31 Jan 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sumitomo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 342,665 | -279,457 | 353,657 | 88,553 |
| 30 Jun 24 | 329,547 | -260,167 | 400,005 | 97,917 |
| 31 Mar 24 | 314,558 | -314,969 | 397,705 | 112,637 |
| 31 Dec 23 | 330,307 | -173,718 | 241,301 | 129,509 |
| 30 Sep 23 | 388,897 | -134,970 | 319,776 | 132,234 |
| 30 Jun 23 | 471,354 | -144,485 | 336,814 | 135,280 |
| 31 Mar 23 | 555,544 | -74,512 | 339,212 | 131,858 |
| 31 Dec 22 | 588,228 | -8,448 | 317,779 | 103,117 |
| 30 Sep 22 | 585,594 | 12,680 | 277,888 | 99,177 |
| 30 Jun 22 | 588,715 | 82,719 | 232,567 | 96,896 |
| 31 Mar 22 | 560,035 | 56,413 | 217,339 | 94,903 |
| 31 Dec 21 | 553,262 | 32,321 | 215,676 | 128,794 |
| 30 Sep 21 | 548,184 | 55,372 | 220,722 | 93,741 |
| 30 Jun 21 | 513,291 | 42,762 | 186,715 | 129,367 |
| 31 Mar 21 | 515,952 | 56,219 | 173,666 | 132,682 |
| 31 Dec 20 | 520,477 | 67,031 | 192,295 | 103,086 |
| 30 Sep 20 | 513,627 | 47,720 | 190,219 | 104,167 |
| 30 Jun 20 | 499,105 | 52,309 | 164,201 | 120,800 |
| 31 Mar 20 | 482,732 | 40,753 | 143,076 | 115,112 |
| 31 Dec 19 | 469,413 | 52,637 | 120,924 | 124,091 |
| 30 Sep 19 | 463,715 | 51,088 | 120,595 | 121,193 |
| 30 Jun 19 | 460,840 | 40,083 | 150,218 | 101,556 |
| 31 Mar 19 | 459,267 | 48,627 | 172,581 | 102,364 |
| 31 Dec 18 | 449,588 | 42,826 | 179,466 | 80,994 |
| 30 Sep 18 | 452,530 | 46,430 | 183,812 | 87,868 |
| 30 Jun 18 | 466,452 | 54,285 | 180,247 | 87,859 |
| 31 Mar 18 | 466,838 | 53,448 | 177,113 | 86,928 |
| 31 Dec 17 | 470,252 | 50,011 | 189,681 | 91,555 |
| 30 Sep 17 | 454,013 | 52,956 | 178,920 | 83,457 |
| 30 Jun 17 | 424,447 | 35,035 | 173,780 | 81,413 |
| 31 Mar 17 | 411,638 | 28,991 | 172,335 | 80,819 |
| 31 Dec 16 | 404,181 | 30,923 | 168,387 | 80,247 |
| 30 Sep 16 | 402,368 | 22,405 | 169,998 | 79,577 |
| 30 Jun 16 | 408,566 | 27,122 | 172,500 | 81,264 |
| 31 Mar 16 | 403,206 | 24,697 | 174,052 | 82,033 |
| 31 Dec 15 | 396,763 | 19,799 | 175,825 | 79,064 |
| 30 Sep 15 | 392,006 | 16,903 | 175,511 | 78,336 |
| 30 Jun 15 | 379,755 | 15,632 | 175,904 | 76,198 |
| 31 Mar 15 | 371,370 | 15,447 | 170,434 | 71,304 |
| 31 Dec 14 | 382,317 | 19,896 | 178,900 | 72,026 |
| 30 Sep 14 | 384,587 | 23,122 | 174,323 | 71,481 |
| 30 Jun 14 | 387,814 | 21,007 | 158,394 | 70,331 |
| 31 Mar 14 | 387,693 | 20,061 | 171,646 | 69,804 |
| 31 Dec 13 | 363,003 | 12,334 | 138,553 | 68,867 |
Quality Earnings: SMDP.Y is currently unprofitable.
Growing Profit Margin: SMDP.Y is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMDP.Y is unprofitable, and losses have increased over the past 5 years at a rate of 71.7% per year.
Accelerating Growth: Unable to compare SMDP.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SMDP.Y is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: SMDP.Y has a negative Return on Equity (-244.58%), as it is currently unprofitable.